Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Guérin et al.
, Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
, Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (date from earlier preprint)
Mean clinical recovery time reduced from 26 days (SOC) to 9 days, p<0.0001 (HCQ+AZ) or 13 days, p<0.0001 (AZ). No cardiac toxicity. Small retrospective study of 88 patients with case control analysis with matched patients.
risk of death, 61.4% lower, RR 0.39, p = 1.00, treatment 0 of 20 (0.0%), control 1 of 34 (2.9%), NNT 34, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 65.0% lower, relative time 0.35, p < 0.001, treatment 20, control 34.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guérin et al., 31 May 2020, retrospective, France, peer-reviewed, 8 authors, dosage 600mg days 1-10, 7-10 days, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
Abstract: Asian Journal of Medicine and Health
18(7): 45-55, 2020; Article no.AJMAH.59198
Azithromycin and Hydroxychloroquine Accelerate
Recovery of Outpatients with Mild/Moderate
Violaine Guérin1*, Pierre Lévy2, Jean-Louis Thomas1, Thierry Lardenois1,
Philippe Lacrosse1, Emmanuel Sarrazin1, Natacha Regensberg-de Andreis1
and Martine Wonner1
Collectif Laissons Les Médecins Prescrire, France.
Département de Santé Publique, Institut Pierre-Louis de Santé Publique (INSERM UMR S 1136,
EPAR Team), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon,
75020 Paris, France.
This work was carried out in collaboration among all authors. Authors VG and JLT designed the study
and wrote the first draft of the manuscript. Authors VG, TL, ES, NRA, P. Lacrosse and MW followed
the patients. Author P. Lévy performed the statistical analysis. All authors read and approved the final
(1) Dr. John K. Triantafillidis, Iasi University of Medicine and Pharmacy, Romania and IASO General Hospital, Greece.
(2) Darko Nozic, University of Belgrade, Serbia.
(1) Malangori Abdulgani Parande, Byramjee Jeejeebhoy Government Medical College (BJGMC), India.
(2) Olga Rukhmakova, National University of Pharmacy, Ukraine.
Complete Peer review History: http://www.sdiarticle4.com/review-history/59198
Original Research Article
Received 26 June 2020
Accepted 14 July 2020
Published 15 July 2020
Aims: The challenge regarding COVID-19 is to prevent complications and fatal evolution.
Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro. We
aimed to assess the efficacy and safety of AZM alone or combined to HCQ, prescribed, at an early
stage, in patients with Covid-19, in a primary care setting.
Study Design: Retrospective observational study.
Place and Duration of Study: Patients have been followed by private practitioners in France,
between March and April 2020.
Methodology: Eighty-eight patients received either no or a symptomatic treatment (NST) (n=34) or
AZM alone (n=34) or AZM+HCQ (n=20). The efficacy end point was the time to clinical recovery
*Corresponding author: E-mail: firstname.lastname@example.org;
Guérin et al.; AJMAH, 18(7): 45-55, 2020; Article no.AJMAH.59198
and the safety end point was the occurrence of cardiovascular events. To improve the evidence
level, a case-control analysis was performed on a sample of 57 patients (19/group) matched for
age, sex and BMI.
Results: The mean (SD) times to achieve clinical recovery were respectively 25.8 days (11.1), 12.9
days (13.4) and 9.2 days (9.3), showing a statistically significant difference between NST and AZM
alone (p<0.0001) or AZM+HCQ (p<0.0001). The statistical difference between NST and AZM was
confirmed (p=0.0149) as well as the difference with AZM+HCQ (p=0.0002). No cardiac toxicity was
recorded in any patient. No statistical difference was shown between AZM and AZM+HCQ groups,
although the dual therapy tended to be more effective in patients over 50 years, based on an
analysis using the cox model.
Conclusion: AZM and AZM+HCQ favourably impacted the course of the disease. We need trials,
ideally prospective/double blind, to show if a statistical difference can be evidenced with a broader
group, and clarify the..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.